Article
Hematology
Lucy B. Cook, Adrienne A. Phillips
Summary: ATL is an aggressive T-cell malignancy with limited survival outcomes with chemotherapy, but novel therapies like mogamulizumab show promise for different ATL subtypes. The implementation of molecular methods may guide diagnosis and treatment, but universal availability remains a challenge worldwide.
Article
Biochemistry & Molecular Biology
Tomohiro Kozako, Naho Kato, Takeo Ohsugi, Yu-ichiro Uchida, Makoto Yoshimitsu, Kenji Ishitsuka, Yasuki Higaki, Haruna Sato, Akiyoshi Aikawa, Shin-ichiro Honda
Summary: In this study, researchers found that SRT1720 can induce cell death in adult T-cell leukemia/lymphoma (ATL) cells through apoptosis and autophagy, and it exhibits anti-tumor activity.
Article
Virology
Takuro Kameda, Kotaro Shide, Yuki Tahira, Masaaki Sekine, Seiichi Sato, Junzo Ishizaki, Masanori Takeuchi, Keiichi Akizuki, Ayako Kamiunten, Haruko Shimoda, Takanori Toyama, Kouichi Maeda, Kiyoshi Yamashita, Noriaki Kawano, Hiroshi Kawano, Tomonori Hidaka, Hideki Yamaguchi, Yoko Kubuki, Akira Kitanaka, Hitoshi Matsuoka, Kazuya Shimoda
Summary: A chart survey was conducted in Miyazaki Prefecture, Japan to study the clinical features of indolent adult T-cell leukemia/lymphoma (ATL). The study found that the prognosis of smoldering-type and favorable chronic-type ATL was better compared to unfavorable chronic-type ATL. In addition to conventional factors, the level of soluble interleukin-2 receptor (sIL2-R) may serve as an indicator for guiding treatment.
Article
Hematology
Yuma Sakamoto, Takashi Ishida, Ayako Masaki, Takayuki Murase, Morishige Takeshita, Reiji Muto, Hiromi Iwasaki, Asahi Ito, Shigeru Kusumoto, Nobuaki Nakano, Masahito Tokunaga, Kentaro Yonekura, Yukie Tashiro, Shinsuke Iida, Atae Utsunomiya, Ryuzo Ueda, Hiroshi Inagaki
Summary: TP53 mutations are associated with unfavorable prognosis of ATL, regardless of treatment strategy. The establishment of alternative modalities to overcome the adverse impact of TP53 mutations in patients with ATL is required.
BRITISH JOURNAL OF HAEMATOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Daisuke Nakano, Kenji Ishitsuka, Madoka Ishihara, Ryota Tsuchihashi, Masafumi Okawa, Kazuo Tamura, Junei Kinjo
Summary: In this study, we isolated and identified 32 compounds from Thuja occidentalis extracts, including lignans, terpenoids, and flavonoids. Lignans showed potent anti-proliferative activity in MT-1 and MT-2 cells, with compounds containing a trans-lactone linkage demonstrating increased activity. Diterpenes and biflavones also exhibited moderate activity, suggesting their potential as candidates for treating adult T-cell leukemia/lymphoma.
Article
Chemistry, Multidisciplinary
Daniel A. Rauch, John C. Harding, Lee Ratner, Samuel A. Wickline, Hua Pan
Summary: Adult T-cell leukemia/lymphoma (ATLL) is a rare but highly malignant tumor caused by human T-cell leukemia virus type 1. A nano-delivery system was developed to inhibit NF-kappa B signaling pathways in tumors by delivering siRNA, resulting in significant tumor growth inhibition and enhanced sensitivity to chemotherapy in late-stage ATLL tumors.
Article
Medicine, General & Internal
Atsuko Nasu, Yuka Gion, Yoshito Nishimura, Asami Nishikori, Misa Sakamoto, Yuria Egusa, Azusa Fujita, Tadashi Yoshino, Yasuharu Sato
Summary: The study suggests that the expression of SOX4 and p16 may help differentiate between ATLL and PTCL-NOS, with significantly higher expression of SOX4 in ATLL patients. It is recommended to perform immunohistochemical staining of SOX4 when pathologists face challenges discriminating between the two diseases.
Article
Virology
Carmen de Mendoza, Ariadna Rando, Elisenda Miro, Maria Jose Pena, Iciar Rodriguez-Avial, Diego Ortega, Alejandro Gonzalez-Praetorius, Gabriel Reina, Ilduara Pintos, Maria Jose Pozuelo, Vicente Soriano
Summary: The rate of ATLL is very low in Spain and mostly associated with migrants from HTLV-1 endemic regions. ATLL patients have a poor clinical outcome, with most of them dying within one year. In Spain, HTLV-1 testing should be performed on migrants from HTLV-1 endemic countries and natives who have lived in or had sex partners from such regions.
JOURNAL OF CLINICAL VIROLOGY
(2023)
Review
Biochemistry & Molecular Biology
Shingo Nakahata, Daniel Enriquez-Vera, M. Ishrat Jahan, Kenji Sugata, Yorifumi Satou
Summary: This comprehensive review summarizes the immunopathogenesis of HTLV-1 infection in ATL and discusses clinical findings for developing treatment strategies.
Review
Virology
Takeharu Kato, Yoshitaka Imaizumi, Yasushi Miyazaki
Summary: Nationwide surveys have played an important role in understanding the pathophysiology and prognosis of adult T-cell leukemia/lymphoma (ATL) in Japan. Different surveys have provided information on the classification and prognosis of ATL. Recent surveys have shown an increase in age at onset and a slight improvement in survival rates for certain types of ATL, while little improvement has been observed for others.
Article
Multidisciplinary Sciences
Allisson B. Justino, Rodrigo M. Florentino, Andressa Franca, Antonio C. M. L. Filho, Rodrigo R. Franco, Andre L. Saraiva, Matheus C. Fonseca, Maria F. Leite, Foued Salmen Espindola
Summary: This study investigated the antiproliferative potential of an alkaloid and acetogenin-rich fraction from the fruit peel of Annona crassiflora in HepG2 cells. The treatment with AF-Ac reduced cell viability, proliferation, and migration, possibly through modulation of PCNA and EGFR expression levels, and intracellular Ca2+ mobilization. These findings suggest a growth-inhibitory effect of AF-Ac on HepG2 cells, highlighting new possibilities for further research on the antitumoral potential of A. crassiflora fruit peel.
Review
Oncology
Shugo Sakihama, Kennosuke Karube
Summary: In recent years, researchers have made significant progress in understanding the genomic aberrations of adult T-cell leukemia/lymphoma (ATLL) and their clinical significance. Advanced technology has also revealed novel genetic alterations and the evolutionary processes of tumor cells in ATLL. This review provides a comprehensive overview of the current knowledge on genetic alterations in ATLL, aiming to promote further research in this field.
Article
Pathology
Kyohei Yamada, Hiroaki Miyoshi, Noriaki Yoshida, Joji Shimono, Kensaku Sato, Kazutaka Nakashima, Mai Takeuchi, Fumiko Arakawa, Naoko Asano, Eriko Yanagida, Masao Seto, Koichi Ohshima
Summary: The mRNA expression levels of HBZ and tax in patients with ATLL are associated with clinicopathological characteristics, with different levels of expression impacting disease severity and overall survival time. Patients with high levels of tax expression are at a higher risk of poor prognosis and reduced survival time. Further studies are needed to fully understand the clinical significance of HBZ and tax mRNA expressions in ATLL.
Article
Oncology
Chie Ishikawa, Masachika Senba, Naoki Mori
Summary: In HTLV-1-infected T cell lines, upregulated IPO beta 1 plays a crucial role in inhibiting cell proliferation, and inhibitors can reduce NF-kappa B and AP-1 nuclear transport and DNA binding, induce cell apoptosis, and suppress ATLL cell growth. Additionally, targeting IPO beta 1 may provide new insights for potential ATLL therapies.
INVESTIGATIONAL NEW DRUGS
(2021)
Article
Pathology
Tomoko Tamaki, Kennosuke Karube, Shugo Sakihama, Yuma Tsuruta, Ryoko Awazawa, Masaki Hayashi, Norihiro Nakada, Hirofumi Matsumoto, Nobutake Yagi, Kazuiku Ohshiro, Iwao Nakazato, Sakiko Kitamura, Yukiko Nishi, Takuya Miyagi, Sayaka Yamaguchi, Sawako Nakachi, Satoko Morishimaj, Hiroaki Masuzakij, Kenzo Takahashik, Takuya Fukushimac, Naoki Wadaa
Summary: Adult T-cell leukemia/lymphoma (ATLL) is a mature T-cell tumor caused by HTLV-1. The typical ATLL immunophenotypes include positive expression of CD2, CD3, CD5, CD4, and CD25, and negative or partially positive expression of other markers. This study performed immunohistochemical stains and identified some new findings regarding the immunophenotypic profile of ATLL.
Letter
Hematology
Takashi Ishida, Tatsuro Jo, Shigeki Takemoto, Hitoshi Suzushima, Youko Suehiro, Ilseung Choi, Makoto Yoshimitsu, Yoshio Saburi, Kisato Nosaka, Atae Utsunomiya, Yukio Kobayashi, Kazuhito Yamamoto, Hiroshi Fujiwara, Kenji Ishitsuka, Shinichiro Yoshida, Naoya Taira, Kazunori Imada, Koji Kato, Yukiyoshi Moriuchi, Kenichi Yoshimura, Takeshi Takahashi, Kensei Tobinai, Ryuzo Ueda
BRITISH JOURNAL OF HAEMATOLOGY
(2019)
Article
Immunology
Madoka Kuramitsu, Kazu Okuma, Makoto Nakashima, Tomoo Sato, Daisuke Sasaki, Hiroo Hasegawa, Kazumi Umeki, Ryuji Kubota, Keiko Sasada, Rieko Sobata, Chieko Matsumoto, Noriaki Kaneko, Kenta Tezuka, Sahoko Matsuoka, Atae Utsunomiya, Ki-Ryang Koh, Masao Ogata, Kenji Ishitsuka, Mai Taki, Kisato Nosaka, Kaoru Uchimaru, Masako Iwanaga, Yasuko Sagara, Yoshihisa Yamano, Akihiko Okayama, Kiyonori Miura, Masahiro Satake, Shigeru Saito, Toshiki Watanabe, Isao Hamaguchi
MICROBIOLOGY AND IMMUNOLOGY
(2018)
Article
Oncology
Lucy B. Cook, Shigeo Fuji, Olivier Hermine, Ali Bazarbachi, Juan Carlos Ramos, Lee Ratner, Steve Horwitz, Paul Fields, Alina Tanase, Horia Bumbea, Kate Cwynarski, Graham Taylor, Thomas A. Waldmann, Achilea Bittencourt, Ambroise Marcais, Felipe Suarez, David Sibon, Adrienne Phillips, Matthew Lunning, Reza Farid, Yoshitaka Imaizumi, Ilseung Choi, Takashi Ishida, Kenji Ishitsuka, Takuya Fukushima, Kaoru Uchimaru, Akifumi Takaori-Kondo, Yoshiki Tokura, Atae Utsunomiya, Masao Matsuoka, Kunihiro Tsukasaki, Toshiki Watanabe
JOURNAL OF CLINICAL ONCOLOGY
(2019)
Article
Hematology
Kenji Ishitsuka, Satoshi Yurimoto, Yukie Tsuji, Manabu Iwabuchi, Takeshi Takahashi, Kensei Tobinai
EUROPEAN JOURNAL OF HAEMATOLOGY
(2019)
Article
Oncology
Katsumi Kobata, Shoichi Kimura, Yasuhito Mihashi, Hiromi Iwasaki, Shuichi Nonaka, Shinji Matsumoto, Yasushi Takamatsu, Ilseung Choi, Shigeto Kawauchi, Kenji Ishitsuka, Morishige Takeshita
Article
Oncology
Yoshitaka Imaizumi, Masako Iwanaga, Kisato Nosaka, Kenji Ishitsuka, Kenichi Ishizawa, Shigeki Ito, Masahiro Amano, Takashi Ishida, Naokuni Uike, Atae Utsunomiya, Koichi Ohshima, Junji Tanaka, Yoshiki Tokura, Kensei Tobinai, Toshiki Watanabe, Kaoru Uchimaru, Kunihiro Tsukasaki
Article
Hematology
Kenji Ishitsuka
Summary: ATL is a T-cell malignancy caused by HTLV-1, with a heterogeneous clinical course and subtypes classified as aggressive and indolent. Treatment for ATL should be stratified based on clinical parameters and genetic predictors for better outcomes.
SEMINARS IN HEMATOLOGY
(2021)
Article
Oncology
Shigeki Ito, Masako Iwanaga, Kisato Nosaka, Yoshitaka Imaizumi, Kenji Ishitsuka, Masahiro Amano, Atae Utsunomiya, Yoshiki Tokura, Toshiki Watanabe, Kaoru Uchimaru, Kunihiro Tsukasaki
Summary: This nationwide study analyzed data from patients diagnosed with ATL in 2012-2013, revealing the characteristics and distribution of ATL patients were consistent with previous studies. The study suggested the usefulness and feasibility of the novel data collection method and emphasized the need for a more sophisticated database management system for future continuous surveys.
Letter
Biophysics
Atae Utsunomiya, Masahito Tokunaga, Nobuaki Nakano, Hiroshi Fujiwara, Toshihiro Miyamoto, Masao Ogata, Yasuhiko Miyazaki, Kenji Ishitsuka, Emiko Sakaida, Hirofumi Taji, Toshio Wakayama, Tatsuo Ichinohe, Takahiro Fukuda, Yoshiko Atsuta, Koji Kato, Makoto Yoshimitsu
BONE MARROW TRANSPLANTATION
(2022)
Editorial Material
Hematology
Kenji Ishitsuka
Summary: T-cell lymphomas were previously neglected in terms of basic research, standard therapies, and novel drug development compared to B-cell lymphomas. However, recent advancements in genome-wide analysis have allowed for a better understanding of the molecular pathophysiology of T-cell lymphomas and the development of individualized treatments. This issue of Progress in Hematology focuses on the progress in basic and clinical research on PTCL and ATL.
INTERNATIONAL JOURNAL OF HEMATOLOGY
(2023)
Article
Oncology
Koji Izutsu, Takahiro Kumode, Junichiro Yuda, Hirokazu Nagai, Yuko Mishima, Youko Suehiro, Kazuhito Yamamoto, Tomoaki Fujisaki, Kenji Ishitsuka, Kenichi Ishizawa, Takayuki Ikezoe, Momoko Nishikori, Daigo Akahane, Jiro Fujita, Minh Dinh, David Soong, Hidehisa Noguchi, Jeppe Klint Buchbjerg, Elena Favaro, Noriko Fukuhara
Summary: This study presented the results of epcoritamab monotherapy in Japanese patients, showing durable treatment responses and manageable safety profile. The drug has potential therapeutic effects in relapsed or refractory diffuse large B-cell lymphoma.
Meeting Abstract
Oncology
T. Kozako, T. Ohsugi, M. Yoshimitsu, Y-I. Uchida, K. Ishitsuka, K. Naho, A. Aikawa, S-I. Honda
ANNALS OF ONCOLOGY
(2018)
Meeting Abstract
Oncology
Kenji Ishitsuka
ANNALS OF ONCOLOGY
(2018)
Article
Hematology
Keisuke Kataoka, Masako Iwanaga, Jun-ichirou Yasunaga, Yasunobu Nagata, Akira Kitanaka, Takuro Kameda, Makoto Yoshimitsu, Yuichi Shiraishi, Aiko Sato-Otsubo, Masashi Sanada, Kenichi Chiba, Hiroko Tanaka, Yotaro Ochi, Kosuke Aoki, Hiromichi Suzuki, Yusuke Shiozawa, Tetsuichi Yoshizato, Yusuke Sato, Kenichi Yoshida, Kisato Nosaka, Masakatsu Hishizawa, Hidehiro Itonaga, Yoshitaka Imaizumi, Wataru Munakata, Kotaro Shide, Yoko Kubuki, Tomonori Hidaka, Tsuyoshi Nakamaki, Ken Ishiyama, Shuichi Miyawaki, Ryohei Ishii, Osamu Nureki, Kensei Tobinai, Yasushi Miyazaki, Akifumi Takaori-Kondo, Tatsuhiro Shibata, Satoru Miyano, Kenji Ishitsuka, Atae Utsunomiya, Kazuya Shimoda, Masao Matsuoka, Toshiki Watanabe, Seishi Ogawa
Letter
Hematology
Masahito Tokunaga, Kentaro Yonekura, Daisuke Nakamura, Kouichi Haraguchi, Tomohisa Tabuchi, Satoshi Fujino, Maiko Hayashida, Kenichi Maekawa, Akihiko Arai, Nobuaki Nakano, Yuhei Kamada, Ayumu Kubota, Hirosaka Inoue, Satsuki Owatari, Shogo Takeuchi, Yoshifusa Takatsuka, Maki Otsuka, Shuichi Hanada, Tadashi Matsumoto, Makoto Yoshimitsu, Kenji Ishitsuka, Atae Utsunomiya
BRITISH JOURNAL OF HAEMATOLOGY
(2018)